Monal Therapeutics is a development stage biotechnology company dedicated exclusively to the treatment of cancer. After more than four decades of relentless scientific pursuit, our team has developed a groundbreaking molecular platform that targets the core inflammatory signals that drive cancers progression.

Our next generation approach treats cancer as a pan-inflammatory disease, and our proprietary molecules block the master cytokines responsible for triggering the inflammatory cascade that fuel tumor growth and metastasis. Monal’s molecules shut down tumor signaling and cell migration, disrupting the formation of new metastatic sites and we do so without harming healthy cells and without unwanted side effects.

Our bio-intelligent platform of molecules are capable of dislodging Cytochrome c trapped by a lipid complex in the inner membrane of dysfunctional mitochondria — a crucial step in halting multiple metabolic pathways exploited by cancer to survive and grow. This includes suppressing the production of essential cytokines that tumors depend on to sustain their expansion.

Monal’s therapeutic innovation acts with precision at the cellular level, attacking cancer’s biological code while preserving the body’s integrity.

Our commitment is uncompromising: to scientific truth, and the development of a platform capable of destroying cancer and its progression.